| Not Yet Recruiting | Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy NCT06647602 | University Medical Center Groningen | — |
| Not Yet Recruiting | Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial NCT07485569 | Radboud University Medical Center | Phase 1 |
| Not Yet Recruiting | Empirical Radioactive Iodine Therapy in DTC NCT07453225 | Assiut University | Phase 1 / Phase 2 |
| Recruiting | F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer NCT07436455 | Ankara University | N/A |
| Recruiting | Pembrolizumab in High-risk Thyroid Cancer NCT05852223 | Istituti Clinici Scientifici Maugeri SpA | Phase 2 |
| Recruiting | Sacituzumab govitEcan in THYroid Cancers NCT06235216 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Recruiting | Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) NCT06458036 | Children's Hospital of Philadelphia | Phase 2 |
| Unknown | Recurrence in Patients With Differentiated Thyroid Cancer NCT06154863 | Assiut University | — |
| Recruiting | Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer NCT05783323 | Children's Hospital of Philadelphia | Phase 2 |
| Recruiting | Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer NCT05989425 | Fudan University | Phase 2 |
| Active Not Recruiting | Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. NCT05660954 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Completed | Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer NCT05745363 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Iodine Uptake After a Low Iodine Diet NCT05599139 | University Medical Center Groningen | N/A |
| Recruiting | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With A NCT05538130 | Pfizer | Phase 1 |
| Terminated | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer NCT05014698 | Nantes University Hospital | N/A |
| Recruiting | Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers NCT05604963 | University College, London | N/A |
| Unknown | Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET) NCT04858867 | Leiden University Medical Center | N/A |
| Recruiting | Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma NCT05078853 | Soroka University Medical Center | — |
| Unknown | Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated T NCT04964284 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 |
| Completed | Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Canc NCT04971473 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 |
| Recruiting | Targeted Therapy to Increase RAI Uptake in Metastatic DTC NCT05024929 | Children's Hospital of Philadelphia | — |
| Unknown | Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer NCT04880798 | Peking Union Medical College Hospital | N/A |
| Active Not Recruiting | Lenvatinib in Locally Advanced Invasive Thyroid Cancer NCT04321954 | Massachusetts Eye and Ear Infirmary | Phase 2 |
| Recruiting | Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy NCT06671184 | Shanghai 6th People's Hospital | — |
| Unknown | The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China NCT04857086 | Huazhong University of Science and Technology | — |
| Unknown | The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer NCT04447183 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Unknown | The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyr NCT04563780 | Assiut University | — |
| Unknown | Investigating National Solutions for Personalised Iodine-131 Radiation Exposure NCT04391244 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer NCT05789667 | Regina Elena Cancer Institute | — |
| Completed | A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Proje NCT03986437 | Institut Claudius Regaud | — |
| Completed | Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patien NCT04137185 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficac NCT03416686 | Assistance Publique - Hôpitaux de Paris | N/A |
| Active Not Recruiting | Primary Care Transfer for Thyroid Cancer Patients NCT03794375 | Hospital de Clinicas de Porto Alegre | N/A |
| Recruiting | Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patie NCT03757637 | National Taiwan University Hospital | N/A |
| Active Not Recruiting | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid C NCT03690388 | Exelixis | Phase 3 |
| Terminated | A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer NCT03602495 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 |
| Terminated | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer NCT03630120 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastati NCT03170960 | Exelixis | Phase 1 |
| Terminated | CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer NCT03002623 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer NCT03048877 | Peking Union Medical College Hospital | Phase 3 |
| Completed | Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer NCT02870569 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Unknown | Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China NCT02638077 | Huazhong University of Science and Technology | — |
| Unknown | Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) NCT02586337 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 / Phase 3 |
| Completed | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or R NCT02244463 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis NCT02304757 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Completed | Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors NCT03176485 | University of Arizona | N/A |
| Completed | Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer NCT01876784 | Genzyme, a Sanofi Company | Phase 3 |
| Terminated | Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid C NCT01843062 | AstraZeneca | Phase 3 |
| Completed | Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 NCT02278198 | University of Colorado, Denver | Phase 1 |
| Unknown | Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors NCT01700699 | University of Salerno | — |
| Unknown | PET Evaluation of Recurrent Differentiated Thyroid Cancer NCT01641679 | The Netherlands Cancer Institute | — |
| Completed | PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer NCT03191643 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | Diagnosing Thyroid Cancer Using a Blood Test NCT01586520 | Newcastle-upon-Tyne Hospitals NHS Trust | — |
| Unknown | Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone NCT01263951 | Thomas Jefferson University | Phase 2 |
| Completed | Sutent Adjunctive Treatment of Differentiated Thyroid Cancer NCT00668811 | Medstar Health Research Institute | Phase 2 |
| Completed | A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Succ NCT00295763 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid NCT07115810 | King Faisal Specialist Hospital & Research Center | — |
| Approved For Marketing | An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid NCT02211222 | Eisai Inc. | — |